Despite Advances in Hepatitis C Treatment, More Research Needed (Video)
April 8, 2016
On behalf of IFARA, Liz Highleyman, editor-in-chief of HIVandHepatitis.com, spoke with Jurgen Rockstroh, M.D., Kenneth Sherman, M.D., Ph.D., and Dost Sarpel, M.D., about research on the treatment of hepatitis B and C. One trial found that a six-week course of ledipasvir and sofosbuvir (Harvoni) cleared acute hepatitis C (HCV) in most patients, except for those with very high viral loads. Another study showed that a new HIV drug, cenicriviroc, can inhibit the hepatic fibrosis often experienced by people living with HIV. Risk factors for HCV treatment failure were the focus of a third study. HCV reinfection, as well as a higher risk for developing liver cancer after being cured of this virus, are other areas of concern, as is the need for drugs to re-treat those for whom HCV treatment did not work the first time around.
Watch the video to learn more:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.
Barbara Jungwirth is a freelance writer and translator based in New York.
Follow Barbara on Twitter: @reliabletran.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO. It is a part of the publication The 23rd Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.